These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 8754503

  • 1. [Effect of granulocyte colony-stimulating factor after chemotherapy with CHOP in patients with non-Hodgkin's lymphoma and HIV infection].
    Navarro JT, Ribera JM, Gómez-Espuch J, Feliu E.
    Med Clin (Barc); 1996 Jun 15; 107(3):118-9. PubMed ID: 8754503
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T, Tsuchiya K, Nishioka S, Kitahara T, Ohmori K, Homma A, Aoyma H, Shindoh M, Shirato H.
    Int J Radiat Oncol Biol Phys; 2004 Nov 01; 60(3):847-52. PubMed ID: 15465202
    [Abstract] [Full Text] [Related]

  • 12. [High-dose biweekly CHOP chemotherapy with granulocyte colony-stimulating factor support for patients with aggressive non-Hodgkin lymphoma].
    Taguchi H, Shishido T, Niitsu N, Hiraoka A, Kageyama T, Kanamaru A, Ogawa M.
    Gan To Kagaku Ryoho; 1998 Mar 01; 25(4):523-9. PubMed ID: 9530358
    [Abstract] [Full Text] [Related]

  • 13. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Characteristics of blood cells during peripheral blood stem cell mobilization following chemotherapy in patients with non-Hodgkin's lymphoma].
    Okada Y, Ando M, Kato T, Taji H, Kagami Y, Ogura M, Morishima Y.
    Rinsho Ketsueki; 2000 Feb 01; 41(2):91-6. PubMed ID: 10723236
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
    Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI, Southwest Oncology Group.
    J Clin Oncol; 2003 Jul 01; 21(13):2466-73. PubMed ID: 12829664
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM, Child JA, Cullen MH, Bailey NP, Woodruffe CM, Fletcher J, Earl H, Barnard D.
    Hematol Oncol; 1996 Dec 01; 14(4):193-201. PubMed ID: 9267465
    [Abstract] [Full Text] [Related]

  • 20. The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients.
    Damiani D, Grimaz S, Sperotto A, Geromin A, Skert C, Cerno M, Rinaldi C, Fanin R.
    Adv Clin Path; 2002 Jan 01; 6(1):11-6. PubMed ID: 17582943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.